HR Positive Breast Cancer

AstraZeneca Camizestrant Breast Cancer Treatment Delays Disease Progression by 55%

By Clinical Trials & Data Desk
3 June 2026

The Phase III SERENA-6 trial reveals that switching to AstraZeneca Camizestrant Breast Cancer Treatment yields a 55% reduction in disease progression risk for advanced HR-positive breast cancer patients with emergent ESR1 mutations.

Tag: HR Positive Breast Cancer

AstraZeneca Camizestrant Breast Cancer Treatment Delays Disease Progression by 55%

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement